Omega-3 Fatty Acids and the Cardiovascular System
Abstract
The cardiovascular benefits of Omega-3 polyunsaturated fatty acids (n-3 PUFAs) has been intensely debated in the scientific community, since the initial observation that certain populations with a high dietary intake of n-3 PUFA seemed to have a lower incidence of cardiovascular disease (CVD). Many randomized clinical trials have been performed which have shown conflicting results. In this chapter, the scientific evidence regarding n-3 PUFA and cardiovascular health are reviewed through the evaluation and discussion of important landmark as well as ongoing clinical studies, including recommendations and guidelines from organizations such as the American Heart Association (AHA). The reader will understand the history of research regarding n-3 PUFA and CVD, the reasons for conflicting results in past trials, recommendations to improve future trials, and current medical guideline recommendations.
Read the paper
Related studies
- eggNOG 5.0: a hierarchical, functionally and phylogenetically annotated orthology resource based on 5090 organisms and 2502 viruses
- Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer
- OptiType: precision HLA typing from next-generation sequencing data
- Nicotinic Cholinergic System and COVID-19: In Silico Identification of an Interaction between SARS-CoV-2 and Nicotinic Receptors with Potential Therapeutic Targeting Implications
- Saccharomyces cerevisiae cells have three Omega class glutathione S-transferases acting as 1-Cys thiol transferases
- Hemolysis at low blood flow rates: in-vitro and in-silico evaluation of a centrifugal blood pump
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.